
Novo Nordisk raises cash flow guidance, boosts valuation on strong obesity drug growth and cost control.
Novo Nordisk has increased its free cash flow guidance to DKK 60–70 billion after reporting DKK 28.4 billion in Q3, with a gross margin improvement to 82.1%. The company's obesity drug is expanding internationally, and positive data on a lower-dose v...



